转移性和复发性尤因肉瘤的当前治疗方法。
Current therapeutic approaches in metastatic and recurrent ewing sarcoma.
作者信息
Huang Michael, Lucas Kenneth
机构信息
Division of Pediatric Hematology/Oncology, Department of Pediatrics, H085, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State Hershey Children's Hospital, 500 University Drive, P.O. Box 850, Hershey, PA 17033-0850, USA.
出版信息
Sarcoma. 2011;2011:863210. doi: 10.1155/2011/863210. Epub 2010 Dec 1.
Abstract
Ewing sarcoma (ES) is the second most common type of primary bone malignancy in children and young adults. Survival rates for localized ES have improved to upwards of 70% with aggressive chemotherapy and local control. On the other hand, there has been little improvement in survival rates for patients with metastatic or recurrent ES. Herein we review the different current therapeutic approaches available, including the different upfront and salvage chemotherapy regimens, the role for stem cell transplantation, and potential use of immunotherapy.
摘要
尤因肉瘤（ES）是儿童和年轻成人中第二常见的原发性骨恶性肿瘤类型。通过积极的化疗和局部控制，局限性ES的生存率已提高到70%以上。另一方面，转移性或复发性ES患者的生存率几乎没有改善。在此，我们回顾了目前可用的不同治疗方法，包括不同的一线和挽救性化疗方案、干细胞移植的作用以及免疫疗法的潜在应用。
相似文献
1
Current therapeutic approaches in metastatic and recurrent ewing sarcoma.转移性和复发性尤因肉瘤的当前治疗方法。
Sarcoma. 2011;2011:863210. doi: 10.1155/2011/863210. Epub 2010 Dec 1.
2
Potential approaches to the treatment of Ewing's sarcoma.尤因肉瘤的潜在治疗方法。
Oncotarget. 2017 Jan 17;8(3):5523-5539. doi: 10.18632/oncotarget.12566.
3
Ewing's sarcoma.尤因氏肉瘤。
Am J Health Syst Pharm. 2010 Oct 1;67(19):1599-605. doi: 10.2146/ajhp090526.
4
SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.SRC 家族激酶抑制在尤文肉瘤细胞中诱导 p38 MAP 激酶介导的细胞毒性并减少细胞迁移。
J Cell Physiol. 2017 Jan;232(1):129-35. doi: 10.1002/jcp.25397. Epub 2016 Apr 19.
5
Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report.尤文肉瘤挽救性治疗的化疗免疫治疗：病例报告。
J Oncol Pharm Pract. 2021 Jul;27(5):1281-1283. doi: 10.1177/1078155220965677. Epub 2020 Oct 18.
6
Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.长春新碱、异环磷酰胺和多柔比星用于成人尤文肉瘤的初始治疗。
Oncologist. 2017 Oct;22(10):1271-1277. doi: 10.1634/theoncologist.2016-0464. Epub 2017 Jul 14.
7
EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma.尤因肉瘤中EWS/FLI1靶基因及治疗机会
Front Oncol. 2015 Jul 20;5:162. doi: 10.3389/fonc.2015.00162. eCollection 2015.
8
Ewing sarcoma in adults treated with modern radiotherapy techniques.采用现代放疗技术治疗的成人尤因肉瘤。
Radiother Oncol. 2014 Nov;113(2):248-53. doi: 10.1016/j.radonc.2014.11.023. Epub 2014 Nov 26.
9
Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.尤因肉瘤患者的神经肽Y系统水平和二肽基肽酶活性——与肿瘤表型和生存的关联
Cancer. 2015 Mar 1;121(5):697-707. doi: 10.1002/cncr.29090. Epub 2014 Nov 11.
10
The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm.肿瘤转移与“癌变国家”的复仇之战：肉瘤范例。
Front Oncol. 2012 Jan 16;2:2. doi: 10.3389/fonc.2012.00002. eCollection 2012.
引用本文的文献
1
EWS-RNA Binding Protein 1: Structural Insights into Ewing Sarcoma by Conformational Dynamics Investigations.EWS-RNA结合蛋白1：通过构象动力学研究对尤因肉瘤的结构洞察
Curr Cancer Drug Targets. 2025 Mar 11. doi: 10.2174/0115680096330765250220053705.
2
Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum.影响骶骨原发性尤因肉瘤患者预后的因素
Sarcoma. 2024 Mar 16;2024:4751914. doi: 10.1155/2024/4751914. eCollection 2024.
3
Exploiting the Stemness and Chemoresistance Transcriptome of Ewing Sarcoma to Identify Candidate Therapeutic Targets and Drug-Repurposing Candidates.利用尤因肉瘤的干性和化疗抗性转录组来鉴定候选治疗靶点和药物再利用候选物。
Cancers (Basel). 2023 Jan 26;15(3):769. doi: 10.3390/cancers15030769.
4
High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing's sarcoma: A single institution experience.大剂量化疗后自体造血干细胞移植治疗初发尤文肉瘤成人患者：单中心经验。
Medicine (Baltimore). 2022 Dec 9;101(49):e32213. doi: 10.1097/MD.0000000000032213.
5
Survival Outcomes in Metastatic Ewing Sarcoma Treated With Whole-Lung Radiation.全肺放疗治疗转移性尤因肉瘤的生存结果
Cureus. 2022 Jul 11;14(7):e26750. doi: 10.7759/cureus.26750. eCollection 2022 Jul.
6
Mechanisms, Diagnosis and Treatment of Bone Metastases.机制、诊断与骨转移治疗。
Cells. 2021 Oct 29;10(11):2944. doi: 10.3390/cells10112944.
7
Ewing's sarcoma of the hip: A case report with no evidence of tumor recurrence and literature review.髋部尤因肉瘤：1例无肿瘤复发证据的病例报告及文献综述
Bone Rep. 2021 Sep 22;15:101131. doi: 10.1016/j.bonr.2021.101131. eCollection 2021 Dec.
8
Identifying States of Collateral Sensitivity during the Evolution of Therapeutic Resistance in Ewing's Sarcoma.在尤因肉瘤治疗耐药演变过程中识别侧支敏感性状态
iScience. 2020 Jul 24;23(7):101293. doi: 10.1016/j.isci.2020.101293. Epub 2020 Jun 20.
9
Soft Tissue Special Issue: Adamantinoma-Like Ewing Sarcoma of the Head and Neck: A Practical Review of a Challenging Emerging Entity.软组织专题：头颈部类造釉细胞瘤样尤因肉瘤：对一种具有挑战性的新兴实体的实用综述
Head Neck Pathol. 2020 Mar;14(1):59-69. doi: 10.1007/s12105-019-01098-y. Epub 2020 Jan 16.
10
Adamantinoma-like Ewing Sarcoma of the Salivary Glands: A Newly Recognized Mimicker of Basaloid Salivary Carcinomas.唾液腺似造釉细胞瘤样尤文肉瘤：一种新认识的基底细胞样唾液腺癌的模拟物。
Am J Surg Pathol. 2019 Feb;43(2):187-194. doi: 10.1097/PAS.0000000000001171.
本文引用的文献
1
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.R1507，一种针对胰岛素样生长因子 1 受体的单克隆抗体，用于治疗复发性或难治性尤文肉瘤家族肿瘤的患者：来自 Sarcoma Alliance for Research through Collaboration 协作研究的 II 期结果。
J Clin Oncol. 2011 Dec 1;29(34):4541-7. doi: 10.1200/JCO.2010.34.0000. Epub 2011 Oct 24.
2
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.原发性多发性骨尤文肉瘤：欧洲尤文肉瘤 99 试验的结果。
J Clin Oncol. 2010 Jul 10;28(20):3284-91. doi: 10.1200/JCO.2009.22.9864. Epub 2010 Jun 14.
3
Cytotoxicity of activated natural killer cells against pediatric solid tumors.活化自然杀伤细胞对小儿实体瘤的细胞毒性。
Clin Cancer Res. 2010 Aug 1;16(15):3901-9. doi: 10.1158/1078-0432.CCR-10-0735. Epub 2010 Jun 11.
4
[Targeted treatment of rare connective tissue tumors and sarcomas].[罕见结缔组织肿瘤和肉瘤的靶向治疗]
Bull Cancer. 2010 Jun;97(6):693-700. doi: 10.1684/bdc.2010.1115.
5
The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES).原发、播散、多灶性尤文肉瘤（PDMES）患者的局部治疗价值。
Cancer. 2010 Jan 15;116(2):443-50. doi: 10.1002/cncr.24740.
6
Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.吉西他滨和多西他赛治疗复发/难治性小儿肉瘤
J Pediatr Hematol Oncol. 2009 Oct;31(10):723-9. doi: 10.1097/MPH.0b013e3181b2598c.
7
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.伊立替康和替莫唑胺治疗尤因肉瘤：纪念斯隆凯特琳癌症中心的经验
Pediatr Blood Cancer. 2009 Dec;53(6):1029-34. doi: 10.1002/pbc.22206.
8
Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma.环氧化酶2介导雷帕霉素在尤因肉瘤中的抗血管生成作用。
J Pediatr Surg. 2009 Jun;44(6):1139-46; discussion 1146-7. doi: 10.1016/j.jpedsurg.2009.02.037.
9
KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.杀伤细胞免疫球蛋白样受体-人类白细胞抗原（KIR-HLA）受体-配体错配与儿童转移性实体瘤单倍体相合干细胞移植中的移植物抗肿瘤效应相关。
Pediatr Blood Cancer. 2009 Jul;53(1):120-4. doi: 10.1002/pbc.21955.
10
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.自然杀伤细胞通过自然杀伤细胞群2D（NKG2D）和DNAX辅助分子-1（DNAM-1）受体依赖性途径识别并裂解尤因肉瘤细胞。
Mol Immunol. 2008 Sep;45(15):3917-25. doi: 10.1016/j.molimm.2008.06.016. Epub 2008 Jul 26.
Zotero 插件